Penn Medicine
Help | Search | Site Map | Contact   
faculty photo

Chang-Gyu Hahn, M.D., Ph.D.

Associate Professor of Psychiatry at the Hospital of the University of Pennsylvania
Mood and Anxiety Disorders Clinic, University of Pennsylvania
Director, Neuropsychiatric Signaling Program, University of Pennsylvania
Department: Psychiatry

Contact information
2003 Translational Research Laboratories
125 South 31st Street
Philadelphia, PA 19104-3403
Office: 215-898-8793
Fax: 215-573-2041
Lab: 215-746-0684
Graduate Group Affiliations
Education:
M.D.
Seoul National University, 1981.
Ph.D. (Neurobiology)
University of Connecticut, 1990.
Post-Graduate Training
Resident in Psychiatry, Hospital of the University of Pennsylvania, 1990-1994.
Fellowship, Neuropsychopharmacology, University of Pennsylvania, 1993-1995.
Certifications
Psychiatry – American Board of Psychiatry and Neurology , 1998.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

The primary interest of my laboratory program lies with the molecular and cellular pathophysiology of psychotic and mood disorders. Directing the Neuropsychiatric Signaling Program in the department of psychiatry, my research has a special focus on identifying intracellular and molecular alterations in neural tissues derived from patients and investigating their underlying mechanisms in animal and in vitro models. Examining molecular and cellular processes occurring in patients has been one of fundamental challenges in the field. In response, my laboratory has taken a path of developing new research paradigms to address questions that could not have been otherwise.

There are two lines of research paradigms that we have developed: analyses of subcellular proteome and intracellular signaling in postmortem brains and of olfactory neuroepithelial biopsy tissues derived from patients. Postmortem brain tissues may harbor biological characteristics linked to the subjects’ clinical profiles, but study of intracellular signaling in those tissues has been hampered. To that end, we have established a series of research paradigms to monitor receptor-mediated activation of intracellular signaling to isolate subcellular fractions enriched for post-synaptic density and synaptic membranes, to assess kinase activity in synaptic membranes and to capture protein complexes followed by mass spectrometer based quantitative proteomics. The olfactory neuroepithelial (OE) biopsy approach offers unique opportunities to obtain neural tissues of living patients that can be studied using ex vivo and in vitro paradigms. This paradigm permits us to address clinically relevant molecular and cellular mechanisms of neuropsychiatric illnesses, specifically pertinent to certain phase or state of illnesses. We have established olfactory neuroepithelial cell lines derived from more than 400 subjects with various psychiatric illnesses. Presently we examine these cells for various molecular pathways implicated for schizophrenia, bipolar disorder and depression using an induced neuronal cell paradigm.

1. Finding direct evidence for NMDAR hypofunction in schizophrenia and identifying molecular underpinnings. NMDAR hypofunction is a major pathophysiologic postulate for schizophrenia supported by genetic, pharmacologic and behavioral evidence. A bottleneck however had been that there had been no direct evidence supporting that NMDAR function is indeed decreased in schizophrenia. Using the newly devised postmortem methods described above, we found direct evidence for NMDAR hypofunction, namely decreased tyrosine phosphorylation of NR2 subunits. Subsequently, we found an underlying mechanisms for this dysregulation, Src hypoactivity.

1. Banerjee A, Wang H-Y, Borgmann-Winter KE, MacDonald ML, Stucky A, Kvasic J, James Kaprielian J, Ray R, Egbujo C, Talbot K, Hemby SE, Siegel SJ, Arnold SE, Sleiman P, Chang X, Hakonarson H, Gur RE, Hahn C-G. Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia. Mol Psychiatry. 2014 Oct 21. doi: 10.1038/mp.2014.
2. Hahn CG. A Src link in schizophrenia. Nat Med. 2011 Apr;17(4):425-427.
3. Hahn C-G, Wang, H., Cho D., Talbot K., Gur. R.E., Berrettini, W.H., Bakshi K., Kamins J., Borgmann-Wnter, K.E., Siegel, S.J., Gallop R.J. and Arnold, S.E. (2006) Abnormally enhanced neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nature Medicine, 12(7): 824-828.

2. Development of olfactory neuroepithelial biopsy research methods. Olfactory epithelial biopsy approach offers a unique opportunity to study neural cells derived from patients without genomic reprogramming. We have established several research paradigms, which have permitted us to study intracellular signaling and other neurobiological measures in neural cells from patients.
1. Borgmann-Winter, KE, Wang, H-Y., Ray, R., Willis, B., Moberg,P., Gur, R., Turetsky, B. Hahn, C-G. Altered G Protein Coupling in Olfactory Neuroepithelial Cells from Patients with Schizophrenia. Schizophrenia Bulletin (in press).
2. Egbujo CN, Sinclair D, Borgmann-Winter KE, Arnold SE, Turetsky BI, Hahn C-G. Molecular Evidence for decreased synaptic efficacy in the postmortem olfactory bulbs of individuals with schizophrenia. Schizophrenia Research. 2015 Aug 7 (Epub ahead of print).
3. Borgmann-Winter, KE, Willard, S, Sinclair, D, Mirza, N, Turetsky, B., Berretta, S. Hahn C-G. Translational Potential of Olfactory Neuroepithelium for the Study of Neuropsychiatric Illness. Translational Psychiatry. March 17, e527, 2015.
4. Hahn C-G, Han L-Y, Rawson N.E., Mirza N., Borgmann-Winter K.E., Lenox R.H. and Arnold S.E. (2005) In vivo and in vitro neurogenesis in human olfactory epithelium. J Comparative Neurology 483(2):154-63
5. Hahn C-G, Gomez G., Restrepo D., Friedman E., Josiassen R., Pribitkin E., Lowry L.D. and Rawson N. E. (2005) Aberrant intracellular calcium signaling in olfactory neurons from bipolar patients. Amer. J Psychiatry, 162(3):616-8.

3. Development of research paradigms in postmortem brain studies. Postmortem brains may harbor critical information pertinent to pathophysiology of brain disorders; yet most of the studies had been limited to expression analyses, i.e., protein or mRNA quantification. We have developed a series of methods towards the goal of assessment of intracellular signaling activity, intracellular trafficking of proteins and protein interactions. They include the postmortem brain receptor activation paradigm, in which intracellular signaling mechanisms are monitored in postmortem brain tissues (Hahn et al, 2006, Nature Medicine), recently biochemical fractionation and proteomic analyses of postmortem brains (Hahn et al, 2009, PLoS ONE) and SRM-LC-MS method (MacDonald, 2012). These methods are seen as highly novel and critical methods and are currently being used by several laboratories world wide.
1. Macdonald ML, Ciccimaro E, Prakash A, Banerjee A, Seeholzer SH, Blair IA, Hahn CG. (2012) Bioochemical Fractionation and Stable Isotope Dilution Liquid Chromatography-Mass Spectrometry for Targeted and Microdomain-Specific Protein Quantification in Human Postmortem Brain Tissue. Mol Cell Proteomics. PMID: 22942359
2. Hahn CG, MacDonald ML, Banerjee A, Cho D, Kamins J, Nie Z, , Grosser T, Borgmann-Winter KB, Angel Pizarro3, Eugene Ciccimaro5,Steven E. Arnold, Hoau-Yan Wang , I.A. Blair. The post-synaptic density of human postmortem brain tissues as a pathophysiologic study paradigm. PLoS One. 2009;4(4):e5251.

Description of Clinical Expertise

My clinical expertise lies with psychopharmacology and various modalities of psychotherapy including dynamically oriented psychotherapy as well as eclectic incorporation of these into day to day clinical practice. Here, I itemize each component as below.

1. Psychopharmacology: My expertise in psychopharmacology stems from my interest in neurobiological underpinnings of psychiatric illnesses that I have pursued throughout my career. Mood disorders are my special interest including depression, bipolar disorder and anxiety disorder. Before I came to Penn, I had founded Bipolar disorders clinic at the Medical College of Pennsylvania _ Hahnemann University where I conducted consultations and supervision for other physicians. At Penn, I have been integral to the Bipolar Disorders Program led by Dr. Lazlo Gyulai, Mood and Anxiety Disorder Research Section directed by Dr. Michael Thase, and Mood and anxiety Disorders Section directed Dr. Karl Rickels. In addition, I have been the primary psychiatrist for most of patients at Dr. Edna Foa's Treatment and Research of Anxiety Disorders Unit, in which I have conducted consultations and pharmacotherapy for patients with PTSD, social phobia and obsessive compulsive disorders.

2. Psychotherapy: My clinical practice is based on applying various psychotherapy modalities in all patient contacts. I have a life long interest in dynamically oriented (or analytically oriented) psychotherapy. My expertise in this modality is largely attributed to my personal psychoanalysis, object relations based, which entailed 4 to 5 sessions a week spanning about 8 years. My expertise has been further equipped with cognitive behavior therapy, exposure therapy and other short term modalities. These modalities are integrated into my day to day practices including what may appear to be cut and dry psychopharmacology based patient contacts.

3. Neurobiological understanding of psychiatric illnesses: The current diagnostic system defines illnesses based on symptom clustering, as abundantly noted in the field. As a neuroscientist with interest in molecules to brain circuitry, I believe that I bring a fairly rare expertise of incorporating updated understanding of brain functioning and its possible dysregulations, which can be reflected in conceptualization of the illnesses and constructing treatment plans.

Together, these expertise permit me to provide specialized yet eclectic clinical practices, which I have applied to supervision of residents and students as well as to patient care.

Selected Publications

Turetsky Bruce I, Hahn Chang-Gyu, Arnold Steven E, Moberg Paul J: Olfactory receptor neuron dysfunction in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 34(3): 767-74, Feb 2009.

Borgmann-Winter K E, Rawson N E, Wang H-Y, Wang H, Macdonald M L, Ozdener M H, Yee K K, Gomez G, Xu J, Bryant B, Adamek G, Mirza N, Pribitkin E, Hahn C-G: Human olfactory epithelial cells generated in vitro express diverse neuronal characteristics. Neuroscience 158(2): 642-53, Jan 2009.

McNamara Robert K, Hahn Chang-Gyu, Jandacek Ronald, Rider Therese, Tso Patrick, Stanford Kevin E, Richtand Neil M: Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biological psychiatry 62(1): 17-24, Jul 2007.

Hahn Chang-Gyu, Wang Hoau-Yan, Cho Dan-Sung, Talbot Konrad, Gur Raquel E, Berrettini Wade H, Bakshi Kalindi, Kamins Joshua, Borgmann-Winter Karin E, Siegel Steven J, Gallop Robert J, Arnold Steven E: Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nature medicine 12(7): 824-8, Jul 2006.

Hahn Chang-Gyu, Umapathy , Wang Hoau-Yan, Koneru Ramesh, Levinson Douglas F, Friedman Eitan: Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. Journal of psychiatric research 39(4): 355-63, Jul 2005.

Hahn Chang-Gyu, Gomez George, Restrepo Diego, Friedman Eitan, Josiassen Richard, Pribitkin Edmund A, Lowry Louis D, Gallop Robert J, Rawson Nancy E: Aberrant intracellular calcium signaling in olfactory neurons from patients with bipolar disorder. The American journal of psychiatry 162(3): 616-8, Mar 2005.

Hahn Chang-Gyu, Han Li-Ying, Rawson Nancy E, Mirza Natasha, Borgmann-Winter Karin, Lenox Robert H, Arnold Steven E: In vivo and in vitro neurogenesis in human olfactory epithelium. The Journal of comparative neurology 483(2): 154-63, Mar 2005.

Talbot Konrad, Eidem Wess L, Tinsley Caroline L, Benson Matthew A, Thompson Edward W, Smith Rachel J, Hahn Chang-Gyu, Siegel Steven J, Trojanowski John Q, Gur Raquel E, Blake Derek J, Arnold Steven E: Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. The Journal of clinical investigation 113(9): 1353-63, May 2004.

Arnold S E, Han L Y, Moberg P J, Turetsky B I, Gur R E, Trojanowski J Q, Hahn C G: Dysregulation of olfactory receptor neuron lineage in schizophrenia. Archives of general psychiatry 58(9): 829-35, Sep 2001.

back to top
Last updated: 11/30/2016
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania. Site best viewed with Mozilla, NN, IE, or Safari.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration